Cargando…
PTX3 from vascular endothelial cells contributes to trastuzumab-induced cardiac complications
AIMS: Trastuzumab, the first humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (ERBB2/HER2), is currently used as a first-line treatment for HER2 (+) tumours. However, trastuzumab increases the risk of cardiac complications without affecting myocardial structure, su...
Autores principales: | Xu, Zhifei, Gao, Zizheng, Fu, Huangxi, Zeng, Yan, Jin, Ying, Xu, Bo, Zhang, Yuanteng, Pan, Zezheng, Chen, Xueqin, Zhang, Xiaochen, Wang, Xiaohong, Yan, Hao, Yang, Xiaochun, Yang, Bo, He, Qiaojun, Luo, Peihua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202646/ https://www.ncbi.nlm.nih.gov/pubmed/36651911 http://dx.doi.org/10.1093/cvr/cvad012 |
Ejemplares similares
-
s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand–foot skin reaction that can be reversed by nicotinamide
por: Luo, Peihua, et al.
Publicado: (2020) -
Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis
por: Yan, Hao, et al.
Publicado: (2023) -
Development and safety of PI3K inhibitors in cancer
por: Yu, Miaomiao, et al.
Publicado: (2023) -
A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors
por: Jin, Ying, et al.
Publicado: (2020) -
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
por: Ai, Leilei, et al.
Publicado: (2020)